MURA Quote, Financials, Valuation and Earnings

Iterum Therapeutics Plc has a net margin of -- compared to Mural Oncology Plc's net margin of -2302.31%. Mural Oncology Plc's return on equity of -111% beat Iterum Therapeutics Plc's return on equity of --.

Mural Oncology Plc has a consensus price target of $5.00, signalling upside risk potential of 194.12%. On the other hand Iterum Therapeutics Plc has an analysts' consensus of $5.50 which suggests that it could grow by 1150%. Given that Iterum Therapeutics Plc has higher upside potential than Mural Oncology Plc, analysts believe Iterum Therapeutics Plc is more attractive than Mural Oncology Plc.

Mural Oncology Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Iterum Therapeutics Plc has a beta of 2.910, suggesting its more volatile than the S&P 500 by 191.032%.

Mural Oncology Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iterum Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mural Oncology Plc pays -- of its earnings as a dividend. Iterum Therapeutics Plc pays out -- of its earnings as a dividend.

Mural Oncology Plc quarterly revenues are --, which are smaller than Iterum Therapeutics Plc quarterly revenues of $390K. Mural Oncology Plc's net income of -$3.7M is higher than Iterum Therapeutics Plc's net income of -$9M. Notably, Mural Oncology Plc's price-to-earnings ratio is -- while Iterum Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mural Oncology Plc is -- versus 41.32x for Iterum Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals Plc has a net margin of -- compared to Mural Oncology Plc's net margin of 22.33%. Mural Oncology Plc's return on equity of -111% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.

Mural Oncology Plc has a consensus price target of $5.00, signalling upside risk potential of 194.12%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $208.50 which suggests that it could grow by 24.92%. Given that Mural Oncology Plc has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Mural Oncology Plc is more attractive than Jazz Pharmaceuticals Plc.

Mural Oncology Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.305, suggesting its less volatile than the S&P 500 by 69.522%.

Mural Oncology Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mural Oncology Plc pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.

Mural Oncology Plc quarterly revenues are --, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Mural Oncology Plc's net income of -$3.7M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Mural Oncology Plc's price-to-earnings ratio is -- while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mural Oncology Plc is -- versus 2.45x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Prothena Corp. Plc has a net margin of -- compared to Mural Oncology Plc's net margin of -1513.09%. Mural Oncology Plc's return on equity of -111% beat Prothena Corp. Plc's return on equity of -67.47%.

Mural Oncology Plc has a consensus price target of $5.00, signalling upside risk potential of 194.12%. On the other hand Prothena Corp. Plc has an analysts' consensus of $20.33 which suggests that it could grow by 82.2%. Given that Mural Oncology Plc has higher upside potential than Prothena Corp. Plc, analysts believe Mural Oncology Plc is more attractive than Prothena Corp. Plc.

Mural Oncology Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Prothena Corp. Plc has a beta of -0.099, suggesting its less volatile than the S&P 500 by 109.869%.

Mural Oncology Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Prothena Corp. Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Mural Oncology Plc pays -- of its earnings as a dividend. Prothena Corp. Plc pays out -- of its earnings as a dividend.

Mural Oncology Plc quarterly revenues are --, which are smaller than Prothena Corp. Plc quarterly revenues of $2.4M. Mural Oncology Plc's net income of -$3.7M is higher than Prothena Corp. Plc's net income of -$36.5M. Notably, Mural Oncology Plc's price-to-earnings ratio is -- while Prothena Corp. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mural Oncology Plc is -- versus 50.97x for Prothena Corp. Plc. Usually stocks with elevated PS ratios are considered overvalued.

XOMA Royalty Corp. has a net margin of -- compared to Mural Oncology Plc's net margin of 52.48%. Mural Oncology Plc's return on equity of -111% beat XOMA Royalty Corp.'s return on equity of 17.31%.

Mural Oncology Plc has a consensus price target of $5.00, signalling upside risk potential of 194.12%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $70.67 which suggests that it could grow by 127.01%. Given that Mural Oncology Plc has higher upside potential than XOMA Royalty Corp., analysts believe Mural Oncology Plc is more attractive than XOMA Royalty Corp..

Mural Oncology Plc has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.919%.

Mural Oncology Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Mural Oncology Plc pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Mural Oncology Plc quarterly revenues are --, which are smaller than XOMA Royalty Corp. quarterly revenues of $9.4M. Mural Oncology Plc's net income of -$3.7M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Mural Oncology Plc's price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 41.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Mural Oncology Plc is -- versus 10.83x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.